Question follow-through · 18295
Medical Equipment: Cybersecurity
To ask the Secretary of State for Health and Social Care, how many cybersecurity vulnerabilities affecting medical devices have been reported to the Medicines and Healthcare products Regulatory Agency in each of the last three years.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 13 Jul 2026
- Target answer date
- 15 Jul 2026
- Answer
- 20 Jul 2026 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Opposition Day Motion: Defence spending and readiness - Prime Minister's Amendment · 23 Jun 2026
- Opposition day: Defence spending and readiness · 23 Jun 2026
- Armed Forces Bill Report Stage: Amendment 11 · 22 Jun 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
13 Jul 2026
Question tabled
To ask the Secretary of State for Health and Social Care, how many cybersecurity vulnerabilities affecting medical devices have been reported to the Medicines and Healthcare products Regulatory Agency in each of the last three years.
15 Jul 2026
Target answer date
Date supplied by the official written-questions record.
20 Jul 2026
Answer published
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available ...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Clinical Trials
14 Jul 2026 · To ask the Secretary of State for Health and Social Care, what steps the Department is taking with the devolved administrations to increase the number of patients able to participate in commercial clinical trials across the UK.
Rare Diseases: Genetics
14 Jul 2026 · To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
NHS: Vacancies
15 Jul 2026 · To ask the Secretary of State for Health and Social Care, what discussions he has had with the devolved administrations on developing a coordinated UK approach to addressing shortages in the NHS workforce in key specialties.
Brain Cancer: Health Services
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, what formal mechanisms are in place to ensure that the views of patients, families and brain cancer patient advocacy organisations are reflected in the work of the National Clinical Lead for Rare C
Brain Cancer: Health Services
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, by what date liquid biopsy technologies will be routinely available for brain tumour patients across the NHS; how many additional patients are expected to gain access to targeted or repurposed trea
Cancer: Health Services
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, which recommendations relating to the cancer workforce from previous workforce reviews, task and finish groups, and National Cancer Board workstreams remain outstanding; what assessment has been ma
Cancer: Health Services
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, whether the (a) National Clinical Lead for Rare Cancers and (b) Rare Cancer Specialty Lead have been appointed; if so, on what date, and against which National Cancer Plan commitments they will be
Brain Cancer: Health Services
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, whether his department will consider the appointment of a specific National Clinical Lead for Brain Cancers.
National Cancer Board
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, what key performance indicators and outcome measures will be used to assess the effectiveness of the National Cancer Board; who will be responsible for overseeing delivery of those outcomes; where
Cancer: Health Services
16 Jul 2026 · To ask the Secretary of State for Health and Social Care, what measurable improvements in (a) workforce capacity, (b) research activity, (c) clinical trial access, (d) speed of diagnosis and (e) patient outcomes are expected as a result of the work of the